论文部分内容阅读
AIM:To investigate the expression of the transforminggrowth factor beta 1(TGF-beta 1)mRNA in different stagesof alcoholic liver disease(ALD)and its clinical value.METHODS:One hundred and seven male alcoholics weregrouped by clinical findings into four groups:alcoholabusers without liver impairment(n=22),alcoholicsteatosis(n=30);alcoholic hepatitis(n=31);andalcoholic cirrhosis(n=24).Using peripheral bloodmononuclear cells(PBMC)as samples the gene expressionof TGF-beta 1 was examined quantitatively by reversetranscription polymerase chain reaction(RT-PCR)and dotblot.There are 34 healthy subjects served as control.RESULTS:The expression of TGF-beta 1 from all ALDpatients was significantly greater than that in controls(1.320±1.162 vs 0.808±0.276,P<0.001).The differences of theexpressions were significant between the patients from eachgroups(alcoholic steatosis,alcoholic hepatitis andalcoholic cirrhosis)and the controls(1.168±0.852,1.462±1.657,1.329±0.610 vs 0.808±0.276,P<0.050).Nosignificant differences of TGF-beta 1 mRNA expression wereobserved between alcohol abusers without liver impairmentand controls.The expressions in patients with alcoholichepatitis and alcoholic cirrhosis were significantly greaterthan that in alcohol abusers respectively(1.462±1.657,1.329±0.610 vs 0.841±0.706,P<0.050).No significantdifferences of TGF -beta 1 mRNA expression were observedbetween alcoholic fatty liver men and alcohol abusers.CONCLUSION: TGF-beta 1 expression level can be a risk factor for alcoholic liver disease and might be related to the inflammatory activity and fibrosis of the liver in patients.
AIM: To investigate the expression of the transforming growth factor beta 1 (TGF-beta 1) mRNA in different stages of alcoholic liver disease (ALD) and its clinical value. METHODS: One hundred and seven male alcoholics were grouped by clinical findings into four groups: alcoholabusers without liver impairment (n = 22), alcoholicsteatosis (n = 30); alcoholic hepatitis (n = 31); and alcoholic cirrhosis (n = 24) .Using peripheral bloodmononuclear cells (PBMC) as samples the gene expressionof TGF- quantitatively by reversetranscription polymerase chain reaction (RT-PCR) and dotblot.There are 34 healthy subjects served as control .RESULTS: The expression of TGF-beta 1 from all ALDpatients was significantly greater than that in controls (1.320 ± 1.162 vs 0.808 ± 0.276 , P <0.001). These differences of theexpressions were significant between the patients from eachgroups (alcoholic steatosis, alcoholic hepatitis and alcoholic cirrhosis) and the controls (1.168 ± 0.852, 1.62 ± 1.657, 1.329 ± 0.610 vs 0.808 ± 0.276, P <0.050) .Nosig nificant differences of TGF-beta 1 mRNA expression wereobserved between alcohol abusers without liver impairment and controls. The expressions in patients with alcoholic hepatitis and alcoholic cirrhosis were significantly greaterthan that in alcohol abusers respectively (1.462 ± 1.657, 1.329 ± 0.610 vs 0.841 ± 0.706, P < 0.050) .No significant differences in TGF-betal mRNA expression were observed between alcoholic fatty liver men and alcohol abusers. CONCLUSION: TGF-beta 1 expression level can be a risk factor for alcoholic liver disease and might be related to the inflammatory activity and fibrosis of the liver in patients.